Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sirnaomics’ siRNA Therapeutic To Begin Clinical Trials In China

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Sirnaomics' RNAi therapeutic STP601 will begin clinical trials in China in late 2008, Patrick Lu, founder, president and CEO of Sirnaomics, told PharmAsia News

You may also be interested in...



Alnylam Makes Entry Into Chinese RNAi Market

Chinese small interfering siRNA supplier Shangahi GenePharma has acquired a nonexclusive worldwide license to Alnylam Pharmaceuticals' Kreutzer-Limmer patent group, which is the first business transaction in China made by the Cambridge, Mass.-based RNAi firm

Asia Spotlight: China's Top Drug Distributors Are Soaring

On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at http://pharmasianews.elsevierbi.com/PAN_Trial_LP.html for a free trial.

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel